Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
1.180
+0.025 (2.16%)
At close: Nov 13, 2026, 4:00 PM EST
1.170
-0.010 (-0.85%)
After-hours: Nov 13, 2026, 7:42 PM EST
Tvardi Therapeutics Employees
Tvardi Therapeutics had 12 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes Tvardi Therapeutics the 39,923rd largest employer in the world and 5,960th in the United States.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,171,917
Market Cap
15.74M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 12 | 0 | - |
| Dec 31, 2024 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seres Therapeutics | 66 |
| Acumen Pharmaceuticals | 61 |
| aTyr Pharma | 60 |
| Citius Pharmaceuticals | 23 |
| Bolt Biotherapeutics | 23 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| BioVie | 13 |
TVRD News
- 14 hours ago - Tvardi Therapeutics reports Q3 EPS (48c), consensus (57c) - TheFly
- 14 hours ago - Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update - GlobeNewsWire
- 24 days ago - Tvardi Therapeutics initiated with a Buy at Chardan - TheFly
- 4 weeks ago - Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Tvardi announces publication of preclinical data on STAT3 inhibitor - TheFly
- 7 weeks ago - New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC) - GlobeNewsWire
- 2 months ago - Tvardi Therapeutics assumed with a Buy at Lucid Capital - TheFly
- 2 months ago - Tvardi Therapeutics to Participate in Upcoming Investor Events - GlobeNewsWire